Clinical Trials in Mental Health
Clinical trials in mental health are enormously expensive, complex,
time consuming, labour intensive and logistically challenging.
Unfortunately, many fail as it can be difficult to overcome
Outsourcing studies can also contribute to failure, and many pharmaceutical companies have stopped doing mental
health drug development for this reason.
However, PsiloTec has leveraged decades of expertise in this
area to design studies that minimize these risks.
There is already decades of available scientific data that supports the potential
effectiveness of psilocybin and other psychedelics in treating
various mental health conditions.
To date, three psychedelic development programs have secured
Breakthrough Therapy Designation (BTD) from the
U.S. Food and Drug Administration, significantly shortening
the projected timelines for drug development,
regulatory review and the path to market.
The firms that succeed in this burgeoning market must have
well-funded clinical programs, patentable products,
and a clear, well-defined business development strategy.
PsiloTec believes it meets all of these key criteria.